Moscow, 10 December, 2007

EMD Serono, Inc entered license agreement with Quantum to get an access to Quantum’ small molecule hit identification computational platform and apply it in in-house research.

The Quantum’ industry leading computational drug design technologies is based on applying quantum, molecular and statistical physics in molecular modeling and was successfully applied in different drug discovery projects. The initial term of the agreement is one year. The financial terms of the agreement were not disclosed.

Quantum is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

EMD Serono, Inc. and Merck Serono S.A. are affiliates of Merck KGaA, Darmstadt, Germany, with over 16,000 employees worldwide and a strong presence on all continents.

More From fedichev

• Quantum Pharmaceuticals and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
• Quantum Pharmaceuticals and Tibotec Pharmaceuticals enter antiviral drug discovery collabortaion.
• q-hERG: QUANTUM’s innovative approach to hERG binding calculations is updated to v 2.0

Ask fedichev To Recommend Your Posts

Related posts:

1. Quantum and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
2. Quantum and Tibotec Pharmaceuticals enter antiviral drug discovery collabortaion.
3. Quantum and Institute of Pulmonology entered COPD drug discovery collaboration.
4. HIV-1 integrase drug discovery collaboration
5. Quantum collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.